AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$6.37 USD
-1.28 (-16.73%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.37 USD
-1.28 (-16.73%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth D Momentum B VGM
Zacks News
PRA Health (PRAH) Stock Down 2.8% Despite Q4 Earnings Beat
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the fourth quarter.
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Glaukos' (GKOS) fourth-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.
LHC Group (LHCG) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
LHC Group's (LHCG) fourth-quarter results benefit from organic growth in home health and hospice admissions.
Allscripts (MDRX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Allscripts (MRDX) witnessed expansion in gross margin, driven by better-than-expected software revenues and consistent decline in operating expenses.
Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Amedisys (AMED) fourth-quarter 2020 revenues improve year over year, driven by strong growth across the Home Health and Hospice divisions.
Inogen (INGN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Inogen's (INGN) fourth-quarter results benefit from higher rental revenues and strength in business-to-business revenues.
Nevro (NVRO) Q4 Loss Narrower Than Estimated, Revenues Miss
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.
Merit Medical (MMSI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q4.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Masimo (MASI) continues to gain from its key Product segment, which witnessed solid growth in Q4.
Chemed (CHE) Q4 Earnings Miss Estimates, 2021 Outlook Dull
by Zacks Equity Research
Chemed's (CHE) fourth-quarter 2020 revenues increased 2.1% year over year to $533.3 million.
Fresenius Medical (FMS) Q4 Earnings Beat, Revenues Miss
by Zacks Equity Research
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strength in Health Care Products segment, and performance across EMEA and Asia Pacific.
Medtronic's (MDT) Q3 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
Medtronic (MDT) procedure volumes hurt by resurgence of COVID-19 cases despite increased demand for related diagnostics and therapies.
Integer Holdings (ITGR) Gains 2.4% Post Q4 Earnings Beat
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter results reflect weak segmental performance.
Pacific Biosciences' (PACB) Sequel II Gets Deployed by LabCorp
by Zacks Equity Research
Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.
Avanos Medical (AVNS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the fourth quarter.
AMN Healthcare (AMN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare (AMN) gains from the Nurse and Allied Solutions segment in the fourth quarter.
Integra (IART) Q4 Earnings Top Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Integra (IART) fourth-quarter 2020 revenues fell 1.6% year over year to $388.6 million but rose 5% sequentially.
OPKO Health (OPK) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results benefit from strength in diagnostics.
Repro Med Systems (KRMD) in Focus: Stock Moves 6.8% Higher
by Zacks Equity Research
Repro Med Systems (KRMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bruker's (BRKR) revenues increased 4.6% year over year to $627.5 million but declined 0.4% organically in fourth-quarter fiscal 2020.
Ecolab (ECL) Q4 Earnings In Line With Estimates, Revenues Lag
by Zacks Equity Research
Although Ecolab's (ECL) fourth-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.
DaVita (DVA) Q4 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
DaVita's (DVA) bottomline in Q4 declines year over year.
DexCom (DXCM) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.
Pacific Biosciences (PACB) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.
LabCorp (LH) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
LabCorp's (LH) 2021 guidance projects significant downfall in COVID-related testing revenues.